MedTrace Logo

Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

NCT07646197 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2026-08-06

No results posted yet for this study

Summary

The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver.

* Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm.
* Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention
* Daily log to be completed for tracking peanut consumption
* 2-day Dietary recall at baseline, during Week 6 and Week 12
* Poat intervention Fibro scans for participants with baseline scans available

Conditions

Interventions

OTHER

Peanut consumption

MASLD patients will consume 50 gm of peanut daily for 12 weeks

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-09
Primary Completion
2028-04-06
Completion
2028-06-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07646197 on ClinicalTrials.gov